anmelden
OMX Copenhagen 20
1.544,40
PKT
+5,93
PKT
+0,39
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Copenhagen 20-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 06.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 06.11.24 | Novo Nordisk Neutral | UBS AG | |
| 06.11.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 04.11.24 | Novo Nordisk Neutral | UBS AG | |
| 04.11.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 01.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 31.10.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 31.10.24 | A.P. Moeller - Maersk A-S (B) Neutral | UBS AG | |
| 30.10.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 28.10.24 | Novo Nordisk Neutral | UBS AG | |
| 22.10.24 | Novo Nordisk Halten | DZ BANK | |
| 21.10.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 21.10.24 | Novo Nordisk Underperform | Bernstein Research | |
| 17.10.24 | A.P. Moeller - Maersk A-S (B) Neutral | UBS AG | |
| 15.10.24 | Novo Nordisk Neutral | UBS AG | |
| 10.10.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 03.10.24 | Novo Nordisk Neutral | UBS AG | |
| 27.09.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 23.09.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 20.09.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 20.09.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 20.09.24 | Novo Nordisk Neutral | UBS AG | |
| 12.09.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 11.09.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 11.09.24 | Novo Nordisk Neutral | UBS AG | |
| 10.09.24 | A.P. Moeller - Maersk A-S (B) Underweight | JP Morgan Chase & Co. | |
| 06.09.24 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 05.09.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 28.08.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 09.08.24 | Novo Nordisk Neutral | UBS AG | |
| 08.08.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 08.08.24 | A.P. Moeller - Maersk A-S (B) Underperform | Bernstein Research | |
| 07.08.24 | Novo Nordisk Underperform | Bernstein Research | |
| 07.08.24 | Novo Nordisk Neutral | UBS AG | |
| 07.08.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 07.08.24 | A.P. Moeller - Maersk A-S (B) Neutral | Goldman Sachs Group Inc. | |
| 07.08.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 07.08.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 01.08.24 | Novo Nordisk Neutral | UBS AG |